Education
About Us
Working with TipRanks
Follow Us
Axsome Therapeutics Inc. (AXSM)
:AXSM
AXSM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$64.11 - $139.13
Previous CloseN/A
Volume140.83K
Average Volume (3M)702.22K
Market Cap
$5.69B
Enterprise Value$3.99B
Total Cash (Recent Filing)-$2.09M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.97
Next Earnings
May 12, 2025EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding48,765,404
10 Day Avg. Volume560,120
30 Day Avg. Volume702,219
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.03
Price to Cash Flow (P/CF)-59.00
P/FCF Ratio254.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.34
Enterprise Value/Ebitda-14.55
Forecast
1Y Price Target
$174.29Price Target Upside49.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
---
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommendation rating remains as Outperform.
Clinical Trial ResultsAxsome reported positive data from the ADHD trial with Sunosi (solriamfetol) and stated that the 150 mg dose achieved statistically significant improvement.
Product GrowthAuvelity growth appears to have outperformed its category/class growth, with the antidepressant and antipsychotic analogs showing declines.
Bears Say
Clinical Trial ConcernsThe 300mg dose did not achieve statistical significance on the study's primary endpoint and had an increased dropout rate.
Market Launch ChallengesSolriamfetol is expected to face a difficult launch due to its late-mover status and pending pediatric study.
Sales PotentialSolriamfetol's efficacy is on par with non-stimulants, which limits its peak sales potential to $500 million.
---
Ownership Overview
1.41% Insiders
19.33% Mutual Funds
35.50% Other Institutional Investors
30.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AXSM FAQ
What was Axsome Therapeutics Inc.’s price range in the past 12 months?
Axsome Therapeutics Inc. lowest stock price was $64.11 and its highest was $139.13 in the past 12 months.
What is Axsome Therapeutics Inc.’s market cap?
Axsome Therapeutics Inc.’s market cap is $5.69B.
When is Axsome Therapeutics Inc.’s upcoming earnings report date?
Axsome Therapeutics Inc.’s upcoming earnings report date is May 12, 2025 which is in 40 days.
How were Axsome Therapeutics Inc.’s earnings last quarter?
Axsome Therapeutics Inc. released its earnings results on Feb 18, 2025. The company reported -$1.54 earnings per share for the quarter, missing the consensus estimate of -$1.001 by -$0.539.
Is Axsome Therapeutics Inc. overvalued?
According to Wall Street analysts Axsome Therapeutics Inc.’s price is currently Undervalued.
Does Axsome Therapeutics Inc. pay dividends?
Axsome Therapeutics Inc. does not currently pay dividends.
What is Axsome Therapeutics Inc.’s EPS estimate?
Axsome Therapeutics Inc.’s EPS estimate is -1.29.
How many shares outstanding does Axsome Therapeutics Inc. have?
Axsome Therapeutics Inc. has 48,765,404 shares outstanding.
What happened to Axsome Therapeutics Inc.’s price movement after its last earnings report?
Axsome Therapeutics Inc. reported an EPS of -$1.54 in its last earnings report, missing expectations of -$1.001. Following the earnings report the stock price went down -2.333%.
Which hedge fund is a major shareholder of Axsome Therapeutics Inc.?
Currently, no hedge funds are holding shares in AXSM
---
Axsome Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$174.29 (49.44% Upside)
$174.29 (49.44% Upside)
Blogger Sentiment
Bullish
AXSM Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.15%
12-Months-Change
Fundamentals
Return on Equity
-231.63%
Trailing 12-Months
Asset Growth
-3.36%
Trailing 12-Months
Company Description
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for the management of central nervous system (CNS) disorders. The company is engaged in the development of a diverse portfolio of product candidates, aiming to address unmet medical needs in depression, migraine, narcolepsy, and other CNS conditions. Axsome's innovative approach leverages insights into the biology of CNS disorders to develop differentiated therapeutics.
---
AXSM Company Deck
---
AXSM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Axsome Therapeutics showed strong revenue growth and significant progress in its product pipeline, including new product approvals. However, the company continued to face high net losses and operating expenses, along with challenges in market access and pricing pressures. The overall sentiment of the call is optimistic about future growth, yet tempered by these financial challenges.Read More>---
AXSM Stock 12 Month Forecast
Average Price Target
$174.29
▲(49.44% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Best Analysts Covering AXSM
1 Year
1 Year Success Rate
19/21 ratings generated profit
1 Year Average Return
+49.37%
reiterated a buy rating 7 days ago
Copying Joon Lee's trades and holding each position for 1 Year would result in 90.48% of your transactions generating a profit, with an average return of +49.37% per trade.
---